Despite significant advancements in drug development, classical drug discovery is still unable to target more than 75% of proteins. Target protein degraders (TPDs) can target intracellular proteins through modified cellular protein degradation mechanisms, and will transform treatments in oncology and other indications in the coming decades.
Our long-standing clients include some of the worlds leading brands and forward-thinking corporations.